Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims largely align with core label sections on mechanism (GABAergic action), indications for seizures and panic disorder, dosage considerations, and adverse reactions with relevant drug interactions. There are notable gaps and several claims not supported by the label (e.g., insomnia indication, generic/brand/manufacturer details, certification of approval date, pricing claims).
Category Scores
Accurate Statements
Clonazepam increases GABA activity (GABAergic mechanism) as its action.
PHARMACODYNAMICS
Aurobindo clonazepam works by increasing the activity of GABA, which helps calm brain activity.
PHARMACODYNAMICS
Aurobindo clonazepam is indicated for seizures (epilepsy).
INDICATIONS AND USAGE
Aurobindo clonazepam is indicated for panic disorder.
INDICATIONS AND USAGE
The dosage is individualized and titration may be needed.
DOSAGE AND ADMINISTRATION
The dosage should be gradually increased as needed.
DOSAGE AND ADMINISTRATION
Common adverse effects include drowsiness, dizziness, confusion, memory problems, slurred speech, and changes in appetite or weight.
ADVERSE REACTIONS
Aurobindo clonazepam can interact with antidepressants, antihistamines, muscle relaxants, narcotics, and sedatives.
DRUG INTERACTIONS
Aurobindo clonazepam is available in 0.5 mg, 1 mg, and 2 mg tablet strengths.
HOW SUPPLIED
Unsupported Statements
Clonazepam is a benzodiazepine medication used to treat insomnia.
Insomnia is not listed as an FDA-approved indication in Indications and Usage.
Aurobindo clonazepam is a generic version of Klonopin manufactured by Roche.
Label does not specify brand/generic manufacturer relationships.
Aurobindo clonazepam was first approved by the US FDA in 2004.
Approval date is not provided in the label.
Since then, it has become a popular alternative to branded Klonopin due to its lower price and similar efficacy.
Pricing and comparative efficacy are not discussed in the label.
Aurobindo clonazepam is used to treat anxiety disorders.
Label specifies panic disorder; broad 'anxiety disorders' are not indicated.
Aurobindo clonazepam is indicated for insomnia.
Insomnia is not an FDA-indicated condition in Indications and Usage.
The patent for Klonopin (clonazepam) expired in 2018.
Patent status is not provided in the label.
Generic versions of the medication, including Aurobindo clonazepam, are now available and can be used as a more affordable alternative.
Generic status is not discussed in the label.
Aurobindo clonazepam is used to treat seizures, anxiety disorders, and insomnia.
Insomnia not indicated; anxiety disorders not explicitly listed as a broad indication.
Contradictions
Important Omissions
No discussion of boxed warnings, pregnancy/lactation considerations, pediatric safety, dependence/withdrawal risk, monitoring parameters, and storage conditions beyond general administration.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims align with known adverse reactions and interactions; no new safety concerns introduced by the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Restrict indications to those approved in Indications and Usage (seizures and panic disorder), remove broad or non-listed indications (e.g., insomnia, general anxiety disorders), and avoid brand/generic/manufacturer and pricing statements. Ensure administration and dosage statements reflect label specifics (e.g., tablet strengths and titration guidance) and include any boxed warnings, pregnancy considerations, and monitoring recommendations if present in the label.